Francisco Javier Martínez-Peromingo

Francisco Javier Martínez-Peromingo

Auto-generated profile, based on publicly available information

Francisco Javier Martínez-Peromingo

Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, 28922 Madrid, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
JMJavier Martinez‐Peromingo
Javier Martinez‐Peromingo
JSJose A. Serra‐Rexach
Jose A. Serra‐Rexach
Click on the article title to read more.

2 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
JMJesus San Roman Montero
Jesus San Roman Montero
FCFrancisco Javier Candel
Francisco Javier Candel
JSJuan Carlos Sanz
Juan Carlos Sanz
PHPaloma López Hernández
Paloma López Hernández
RMRocío Menéndez-Colino
Rocío Menéndez-Colino
OSon behalf of the Investigators of the SeroVAC Study
on behalf of the Investigators of the SeroVAC Study
Background: Most residents and staff in nursing homes have received full vaccination. Factors related to the immune response to vaccination might be related to the risk of future severe COVID-19 and may guide the need for vaccine boosters. Design: Nursing homes that were tested in a point survey in July-October 2020 were again analyzed after a vaccination campaign in June-July 2021. Immune responses according to IgG against nucleocapsid and spike antigens, and CD4 and CD8 interferon-gamma release assay against spike antigens, were evaluated. Results: A total of 1973 subjects were tested (61.7% residents, 48.3% staff), with a mean (SD) follow-up of 46.4 (3.6) weeks between assessments. More than half of residents and more than a third of staff had evidence of COVID-19 before vaccination; 26.9% and 22.7% had seroreversion of IgG-N, and 8.9% and 4.6% had IgG-N seroconversion at second assessment, respectively. Up to 96.8% of residents and 98.1% of workers had positive IgG-S after a mean of 19.9 (2.1) weeks after vaccination. In residents with vs without a history of COVID-19, IgG-S titers were 4.11 (0.54) vs. 2.73 (0.74) logAU/mL (p < 0.001); in workers these titers were 3.89 (0.61) vs. 3.15 (0.64) logAU/mL (p < 0.001). Linear regression analysis showed that younger age (OR: −0.03 per 10 years-older [95% CI, −0.04 to −0.02], p < 0.001) and evidence of COVID-19 (OR: 1.14 [95% CI, 1.08 to 1.20], p < 0.001) are associated with greater IgG-S titers after vaccination. A direct association was found between IgG-S titers and the intensity of IFN-gamma response against spike antigens. Conclusions: Waning of humoral response and reinfection seems to be more frequent in older as compared to younger adults, although cellular responses shortly after vaccination are comparable between these groups. Younger age and prior COVID-19 are related to greater humoral response after vaccination against SARS-CoV-2.

27 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
FCFrancisco Javier Candel
Francisco Javier Candel
PBPablo M. Bàrreiro
Pablo M. Bàrreiro
MLMiguel Salavert Lleti
Miguel Salavert Lleti
Alfonso Cabello-UbedaAlfonso Cabello-Ubeda
Alfonso Cabello-Ubeda
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
O(on behalf of the MODUS Investigators (Adenda)
on behalf of the MODUS Investigators (Adenda)
The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The evolution to less aggressive but better-transmitted viral variants, and the presence of immune memory responses in a growing number of vaccinated and/or virus-exposed individuals, has caused the pandemic to slowly wane in virulence. However, there are still patients with risk factors or comorbidities that put them at risk of poor outcomes in the event of having the coronavirus infectious disease 2019 (COVID-19). Among the different treatment options for patients with COVID-19, virus-targeted measures include antiviral drugs or monoclonal antibodies that may be provided in the early days of infection. The present expert consensus is based on a review of all the literature published between 1 July 2021 and 15 February 2022 that was carried out to establish the characteristics of patients, in terms of presence of risk factors or comorbidities, that may make them candidates for receiving any of the virus-targeted measures available in order to prevent a fatal outcome, such as severe disease or death. A total of 119 studies were included from the review of the literature and 159 were from the additional independent review carried out by the panelists a posteriori. Conditions found related to strong recommendation of the use of virus-targeted measures in the first days of COVID-19 were age above 80 years, or above 65 years with another risk factor; antineoplastic chemotherapy or active malignancy; HIV infection with CD4+ cell counts < 200/mm3; and treatment with anti-CD20 immunosuppressive drugs. There is also a strong recommendation against using the studied interventions in HIV-infected patients with a CD4+ nadir <200/mm3 or treatment with other immunosuppressants. Indications of therapies against SARS-CoV-2, regardless of vaccination status or history of infection, may still exist for some populations, even after COVID-19 has been declared to no longer be a global health emergency by the WHO.

2 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
FCFernando Cava
Fernando Cava
JMJesus San Roman Montero
Jesus San Roman Montero
PBPablo M. Bàrreiro
Pablo M. Bàrreiro
FCFrancisco Javier Candel
Francisco Javier Candel
FÁFrancisco Javier Álvarez-Timón
Francisco Javier Álvarez-Timón
AZAntonio Zapatero-Gaviria
Antonio Zapatero-Gaviria
Tools to predict surges in cases and hospitalizations during the COVID-19 pandemic may help guide public health decisions. Low cycle threshold (CT) counts may indicate greater SARS-CoV-2 concentrations in the respiratory tract, and thereby may be used as a surrogate marker of enhanced viral transmission. Several population studies have found an association between the oscillations in the mean CT over time and the evolution of the pandemic. For the first time, we applied temporal series analysis (Granger-type causality) to validate the CT counts as an epidemiological marker of forthcoming pandemic waves using samples and analyzing cases and hospital admissions during the third pandemic wave (October 2020 to May 2021) in Madrid. A total of 22,906 SARS-CoV-2 RT-PCR-positive nasopharyngeal swabs were evaluated; the mean CT value was 27.4 (SD: 2.1) (22.2% below 20 cycles). During this period, 422,110 cases and 36,727 hospital admissions were also recorded. A temporal association was found between the CT counts and the cases of COVID-19 with a lag of 9–10 days (p ≤ 0.01) and hospital admissions by COVID-19 (p < 0.04) with a lag of 2–6 days. According to a validated method to prove associations between variables that change over time, the short-term evolution of average CT counts in the population may forecast the evolution of the COVID-19 pandemic.

2 June 2022 in Gerontology
Verified
Journal Article
Open access
PDF file
JRJesús San Román
Jesús San Román
FCFrancisco J. Candel
Francisco J. Candel
MCMaría del Mar Carretero
María del Mar Carretero
JSJuan Carlos Sanz
Juan Carlos Sanz
MPMarta Pérez-Abeledo
Marta Pérez-Abeledo
OSon behalf of the investigators of the SeroSOS study
on behalf of the investigators of the SeroSOS study
Introduction: Nursing homes for older adults have been hot spots for SARS-CoV-2 infections and mortality. Factors that facilitate COVID-19 outbreaks in these settings need to be assessed. Methods: A retrospective cross-sectional study of a cohort of residents and workers in nursing homes taking occasion of a point seroprevalence survey was done in the Community of Madrid. Factors related to outbreaks in these facilities were analyzed. Results: A total of 369 nursing homes for older adults, making a population of 23,756 residents and 20,795 staff members, were followed from July to December 2020. There were 54.2% SARS-CoV-2 IgG+ results in residents and in 32.2% of workers. Sixty-two nursing homes (16.8%) had an outbreak during the follow-up. Nursing homes with outbreaks had more residents than those without (median number of 81 [IQR, 74] vs. 50 [IQR, 56], p < 0.001). Seropositivity for SARS-CoV-2 was lower in facilities with versus without outbreaks, for residents (42.2% [IQR, 55.7] vs. 58.7% [IQR, 43.4], p = 0.002) and for workers (23.9% [IQR, 26.4] vs. 32.8% [IQR, 26.3], p = 0.01). For both residents and staff, the number of infections in outbreaks was larger in centers with lower, as compared with intermediate or high seroprevalence. The size of the facility did not correlate with the number of cases in the outbreak. Taking the incidence of cases in the community as a time-dependent variable (p = 0.03), a Cox analysis (HR [95% CI], p) showed that intermediate or high seroprevalence among residents in the facility was related to a reduction of 55% (0.45 [0.25–0.80], p = 0.007) and 78% (0.22 [0.10–0.48], p < 0.001) in the risk of outbreaks, respectively, as compared with low sero­prevalence. Also, as compared with smaller, medium (1.91 [1.00–3.65], p = 0.05) or large centers (4.57 [2.38–8.75], p < 0.001) had more respective risk of outbreaks. Conclusions: The size of the facility and the seroprevalence among residents in nursing homes, and the incidence of infections in the community, are associated with the risk of outbreaks of COVID-19. Facilities with greater proportion of seropositives had smaller number of cases. Monitoring of immunity in nursing homes may help detect those at a greater risk of future cases.

3 April 2023 in Revista Española de Geriatría y Gerontología
Verified
Journal Article
Closed access
JMJavier Martínez-Peromingo
Javier Martínez-Peromingo
RCRaul Cordoba
Raul Cordoba
BFBernadette Fang
Bernadette Fang
RGRegina Girones
Regina Girones